Q96RI1 (NR1H4_HUMAN) Homo sapiens (Human)
Bile acid receptor UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
86 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| FXR with SRC1 and GSK088 |
Heteromer Q15788; | 99.13 | 1×088; 1×SO4; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9LA; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9MM; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9LS; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9ND; | |||
| Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimida… |
Heteromer Q15788; | 99.13 | 1×OMK; | |||
| Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… |
Heteromer Q15788; | 99.13 | 1×OLF; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9MP; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9MD; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9MY; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×CL; 1×9L7; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9LP; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9N1; | |||
| Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2… |
Heteromer Q15788; | 99.13 | 1×OKI; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9N4; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9MS; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9KV; | |||
| Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… |
Heteromer Q15788; | 99.13 | 1×OMM; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9LY; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9M1; | |||
| Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… |
Heteromer Q15788; | 99.13 | 1×OOK; | |||
| Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… |
Heteromer Q15788; | 99.13 | 1×OOF; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9N7; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9NA; | |||
| A unique binding model of FXR LBD with feroline |
Heteromer Q15596; | 100 | 1×FEZ; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9LJ; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.13 | 1×9KY; | |||
| FXR with SRC1 and GW4064 |
Heteromer Q15788; | 100 | 1×064; | |||
| FXR with SRC1 and GSK237 |
Heteromer Q15788; | 100 | 2×SO4; 1×37G; | |||
| FXR-LBD with HNC180 and SRC1 |
Heteromer Q15788; | 99.13 | 5×SO4; 1×9R3; | |||
| FXR with SRC1 and GSK826 |
Heteromer Q15788; | 100 | 1×82X; 2×SO4; | |||
| FXR with DM175 and NCoA-2 peptide |
Heteromer Q15596; | 100.0 | 1×31D; 4×EDO; | |||
| FXR with SRC1 and GSK8062 |
Heteromer Q15788; | 100 | 1×O62; | |||
| FXR bound to isoquinolinecarboxylic acid |
Heteromer Q15788; | 98.69 | 1×P88; 1×SO4; | |||
| A ligand F binding to FXR |
Heteromer Q15596; | 100 | 1×93R; | |||
| FXR with SRC1 and GSK359 |
Heteromer Q15788; | 100 | 2×SO4; 1×59G; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q9UBK2; | 99.11 | 1×0X0; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.1 | 1×9NM; | |||
| Crystal structure of human FXR in complex with a functional drug ligand |
Heteromer Q15596; | 98.23 | 1×D5H; | |||
| Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC143 and 9cRA and SRC1 |
Heteromer P19793; Q15788; | 99.12 | 1×9R0; 2×SO4; 1×9CR; 1×PO4; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.09 | 1×9LM; | |||
| CRYSTAL STRUCTURE OF FARNESOID X-ACTIVATED RECEPTOR COMPLEXED WITH COMPOUND-32 AKA (1S,3S)-N-({4-[5… |
Heteromer Q15788; | 99.55 | 1×IUS; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.12 | 1×9NP; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.09 | 1×643; | |||
| Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist |
Heteromer Q15788; | 99.09 | 1×643; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.12 | 1×9NJ; | |||
| A novel moderator XD4 for bile acid receptor |
Heteromer Q15788; | 99.05 | 1×XD4; 1×SO4; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.12 | 1×9L4; | |||
| Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexy… |
Heteromer Q15788; | 99.12 | 2×OKH; | |||
| Crystal structure of FXR in complex with agonist XJ034 |
Heteromer Q15788; | 99.11 | 1×AWL; | |||
| Novel natural FXR modulator with a unique binding mode |
Heteromer Q15596; | 100 | 2×T73; | |||
| FXR ligand binding domain |
Heteromer Q15596; | 100.0 | 1×93U; | |||
| A structure of FXR/RXR |
Heteromer P19793; Q15596; | 100.0 | 1×33Y; 1×9CR; | |||
| FXR-LBD with HNC143 and SRC1 |
Heteromer Q15788; | 99.12 | 1×9R0; | |||
| Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC180 and 9cRA and SRC1 |
Heteromer P19793; Q15788; | 99.09 | 1×9R3; 1×9CR; | |||
| A ligand binding to FXR |
Heteromer Q15596; | 100.0 | 1×93O; | |||
| Structural basis for a pentacyclic oleanane-type triterpenoid as a ligand of FXR |
Heteromer Q15596; | 100.0 | 1×7VX; 3×BU3; | |||
| Crystal structure of human FXR/RXR-LBD heterodimer bound to GW4064 and 9cRA and SRC1 |
Heteromer P19793; Q15788; | 99.09 | 1×064; 1×9CR; | |||
| FXR with SRC1 and GSK2034 |
Heteromer Q15788; | 100 | 1×SO4; 1×034; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.1 | ||||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.1 | 1×9NG; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.12 | 1×9LV; | |||
| Structure of human FXR in complex with MFA-1 and co-activator peptide |
Heteromer Q15788; | 100.0 | 1×YT3; 1×MUF; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.1 | 1×9LG; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.11 | 1×9O1; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.12 | 1×9MA; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15596; | 99.1 | 1×9MV; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.1 | 1×9L1; | |||
| A moderator XD22 binding to bile acid receptor |
Heteromer Q15596; | 100.0 | 1×XD5; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.09 | 1×9LD; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.11 | 1×9M4; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q15788; | 99.09 | 1×9M7; | |||
| A ligand M binding to FXR |
Heteromer Q15596; | 100.0 | 1×NIW; | |||
| Structural insight of the molecular mechanism of cilofexor bound to FXR |
Heteromer Q15596; | 100 | 1×811; | |||
| Structural basis of tropifexor as a potent and selective agonist for farnesoid X receptor |
Heteromer Q15596; | 100.0 | 1×GWF; | |||
| FXR bound to a quinolinecarboxylic acid |
Heteromer Q15788; | 99.1 | 1×89P; 1×SO4; | |||
| Identification of a novel FXR ligand that regulates metabolism |
Heteromer O75376; | 100.0 | 4×FMT; 1×IVM; | |||
| Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA |
Heteromer P19793; | 100 | 4×ZN; | |||
| Structural basis for small molecule NDB as a selective antagonist of FXR | homo-2-mer | 99.05 | 2×XX9; | |||
| Crystal Structure of Farnesoid X receptor (FXR) with bound NCoA-2 peptide and CDCA | monomer | 100.0 | 1×JN3; | |||
| A Chemical, Genetic, and Structural Analysis of the nuclear bile acid receptor FXR | monomer | 99.53 | 1×FEX; | |||
| Crystal Structure of Farnesoid X receptor (FXR) with bound NCoA-2 peptide | monomer | 100 | ||||
| Complex Structure of FXR Ligand-binding domain with a tetrahydroazepinoindole compound | monomer | 100.0 | 1×635; | |||
| Discovery of XL335, a Highly Potent, Selective and Orally-Active Agonist of the Farnesoid X Recepto… | monomer | 100.0 | 1×33Y; | |||
| Farnesoid X Receptor Agonists_FXR fused with a HD3 peptide | monomer | 99.12 | 1×XAW; | |||
| isoxazole ligand bound to farnesoid X receptor (FXR) | monomer | 99.11 | 1×708; | |||
12 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4nqa.1.B | monomer | 0.61 | 2×ZN; | 36.41 | ||
| 4nqa.2.B | monomer | 0.60 | 2×ZN; | 36.41 | ||
| 3dzy.1.B | monomer | 0.59 | 1×ZN; | 29.68 | ||
| 4nqa.1.A | monomer | 0.57 | 2×ZN; | 26.48 | ||
| 7prv.1.A | monomer | 0.56 | 2×ZN; | 22.36 | ||
| 7prv.1.B | monomer | 0.56 | 2×ZN; | 22.36 | ||
| 5uan.1.A | monomer | 0.56 | 2×ZN; | 26.48 | ||
| 7wnh.4.A | monomer | 0.55 | 2×ZN; | 29.81 | ||
| 3dzy.1.A | monomer | 0.54 | 2×ZN; | 26.32 | ||
| 7wnh.2.A | monomer | 0.54 | 2×ZN; | 29.81 | ||
| 4nqa.1.A | monomer | 0.53 | 2×ZN; | 28.53 | ||
| 4nqa.2.A | monomer | 0.52 | 1×ZN; | 28.53 | ||
42 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 1 | 4nqa.1.B | monomer | 0.61 | 2×ZN; | 36.69 | ||
| Isoform 1 | 4nqa.2.B | monomer | 0.59 | 2×ZN; | 36.69 | ||
| Isoform 1 | 3dzy.1.B | monomer | 0.59 | 1×ZN; | 29.68 | ||
| Isoform 1 | 7prv.1.A | monomer | 0.57 | 2×ZN; | 22.59 | ||
| Isoform 1 | 7wnh.4.A | monomer | 0.55 | 2×ZN; | 29.81 | ||
| Isoform 1 | 7prv.1.B | monomer | 0.55 | 2×ZN; | 22.59 | ||
| Isoform 1 | 3dzy.1.A | monomer | 0.54 | 2×ZN; | 26.63 | ||
| Isoform 1 | 7wnh.2.A | monomer | 0.54 | 2×ZN; | 29.81 | ||
| Isoform 1 | 5uan.1.A | monomer | 0.53 | 2×ZN; | 28.53 | ||
| Isoform 1 | 4nqa.1.A | monomer | 0.53 | 2×ZN; | 28.53 | ||
| Isoform 1 | 4nqa.2.A | monomer | 0.52 | 1×ZN; | 28.53 | ||
| Isoform 2 | 4nqa.1.B | monomer | 0.64 | 2×ZN; | 38.42 | ||
| Isoform 2 | 4nqa.2.B | monomer | 0.62 | 2×ZN; | 38.42 | ||
| Isoform 2 | 5uan.1.B | monomer | 0.61 | 1×ZN; | 31.10 | ||
| Isoform 2 | 3dzy.1.B | monomer | 0.60 | 1×ZN; | 29.39 | ||
| Isoform 2 | 4nqa.1.A | monomer | 0.58 | 2×ZN; | 27.73 | ||
| Isoform 2 | 5uan.1.A | monomer | 0.57 | 2×ZN; | 27.73 | ||
| Isoform 2 | 3dzy.1.A | monomer | 0.57 | 2×ZN; | 26.63 | ||
| Isoform 2 | 7prv.1.B | monomer | 0.56 | 2×ZN; | 22.66 | ||
| Isoform 2 | 7prv.1.A | monomer | 0.56 | 2×ZN; | 22.66 | ||
| Isoform 2 | 7wnh.4.A | monomer | 0.56 | 2×ZN; | 29.49 | ||
| Isoform 2 | 7wnh.2.A | monomer | 0.55 | 2×ZN; | 29.49 | ||
| Isoform 4 | 4nqa.1.B | monomer | 0.64 | 2×ZN; | 37.96 | ||
| Isoform 4 | 4nqa.2.B | monomer | 0.62 | 2×ZN; | 37.96 | ||
| Isoform 4 | 3dzy.1.B | monomer | 0.59 | 1×ZN; | 29.39 | ||
| Isoform 4 | 4nqa.1.A | monomer | 0.58 | 2×ZN; | 27.73 | ||
| Isoform 4 | 5uan.1.A | monomer | 0.57 | 2×ZN; | 27.73 | ||
| Isoform 4 | 7wnh.4.A | monomer | 0.56 | 2×ZN; | 29.49 | ||
| Isoform 4 | 3dzy.1.A | monomer | 0.56 | 2×ZN; | 27.33 | ||
| Isoform 4 | 7wnh.2.A | monomer | 0.55 | 2×ZN; | 29.49 | ||
| Isoform 4 | 7kw7.1.F | monomer | 0.54 | 23.80 | |||
| Isoform 5 | 4nqa.1.B | monomer | 0.66 | 1×ZN; | 33.55 | ||
| Isoform 5 | 4nqa.2.B | monomer | 0.64 | 33.55 | |||
| Isoform 5 | 4nqa.1.A | monomer | 0.60 | 22.56 | |||
| Isoform 5 | 5uan.1.A | monomer | 0.60 | 1×ZN; | 22.56 | ||
| Isoform 5 | 3dzy.1.A | monomer | 0.60 | 22.48 | |||
| Isoform 5 | 7prw.1.B | monomer | 0.58 | 1×ZN; | 20.20 | ||
| Isoform 5 | 7prv.1.A | monomer | 0.58 | 20.20 | |||
| Isoform 5 | 4nqa.2.A | monomer | 0.57 | 22.56 | |||
| Isoform 5 | 7wnh.2.A | monomer | 0.52 | 27.31 | |||
| Isoform 5 | 7wnh.4.A | monomer | 0.52 | 1×ZN; | 27.31 | ||
| Isoform 5 | 4iqr.2.A | monomer | 0.51 | 1×ZN; | 34.38 | ||